GO:2001301 lipoxin biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001301 (lipoxin biosynthetic process) describes the enzymatic formation of lipoxins, non-classic eicosanoid signaling molecules derived from arachidonic acid.
• Lipoxin biosynthesis proceeds through sequential lipoxygenase reactions, including 5-lipoxygenase (ALOX5), 12-lipoxygenase (ALOX12), and 15-lipoxygenase (ALOX15) activities, often via transcellular routes.
• Lipoxins are anti-inflammatory and pro-resolving mediators that act through the ALX/FPR2 receptor to promote neutrophil clearance and limit tissue damage.
• Dysregulated lipoxin biosynthesis has been linked to inflammatory diseases, cancer, and impaired resolution programs.
• Key genes in this process include ALOX5, ALOX12, ALOX15, ALOX15B, LTA4H, FPR2/ALX, and PLA2G4A, which provide targets for CRISPR-based functional studies.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of lipoxin pathway genes in inflammation and cancer research.
Description
GO:2001301, lipoxin biosynthetic process, is a biological process term in the Gene Ontology that defines the chemical reactions and pathways resulting in the formation of lipoxins. Lipoxins are non-classic eicosanoids derived from arachidonic acid, characterized by four conjugated double bonds, and they function as signaling molecules in inflammation and its resolution. The term encompasses the enzymatic steps that convert arachidonic acid into lipoxin A4 and related lipoxin species, primarily through lipoxygenase-mediated reactions. Researchers study this process because lipoxins are potent endogenous anti-inflammatory and pro-resolving mediators, and their biosynthesis is often dysregulated in chronic inflammatory diseases and cancer. Understanding the genes and enzymes that execute lipoxin biosynthesis is essential for developing targeted therapies that modulate resolution pathways. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the lipoxin biosynthetic process, its key genes, regulatory features, disease relevance, and experimental models for CRISPR-based investigation.
lipoxin biosynthetic process At A Glance
| GO ID | GO:2001301 |
|---|---|
| GO term | lipoxin biosynthetic process |
| Ontology | biological_process |
| Synonym | lipoxin anabolism; lipoxin biosynthesis; lipoxin formation; lipoxin synthesis |
| Major function | Production of lipoxins, anti-inflammatory and pro-resolving eicosanoid mediators derived from arachidonic acid |
| Key enzymes | ALOX5, ALOX12, ALOX15, ALOX15B, LTA4H, and associated biosynthetic enzymes |
| Substrate | Arachidonic acid and its lipoxygenase-derived intermediates |
| Receptor | ALX/FPR2 mediates lipoxin signaling |
| Disease relevance | Inflammation, cancer, and impaired resolution programs |
What Is GO:2001301?
The lipoxin biosynthetic process (GO:2001301) is the set of chemical reactions and pathways that produce lipoxins. A lipoxin is a non-classic eicosanoid signaling molecule with four conjugated double bonds, derived from arachidonic acid. This process includes the enzymatic oxygenation and conversion steps catalyzed by lipoxygenases and other enzymes, leading to the formation of lipoxin A4 and its isomers.
Why Is lipoxin biosynthetic process Important in Cell Biology?
The lipoxin biosynthetic process is important because lipoxins are endogenous stop signals for inflammation and key drivers of tissue resolution. Dysregulation of this pathway contributes to chronic inflammatory diseases, cancer progression, and impaired host defense. Targeting lipoxin biosynthesis or its receptor ALX/FPR2 offers therapeutic opportunities for resolving inflammation without immunosuppression. Consequently, researchers need robust models to dissect the causal roles of lipoxin pathway genes.
• Lipoxins are anti-inflammatory and pro-resolving mediators that limit neutrophil infiltration and promote macrophage clearance.
• The biosynthetic pathway converts arachidonic acid into lipoxin A4 and related species through lipoxygenase reactions.
• Lipoxin biosynthesis is often dysregulated in chronic inflammatory diseases and cancer.
• ALX/FPR2 receptor signaling mediates many biological effects of lipoxins.
• Enzymes such as ALOX5, ALOX12, and ALOX15 are central to lipoxin formation and are candidate therapeutic targets.
• Transcellular biosynthesis allows cooperation between different cell types to produce lipoxins.
• Lipoxin levels can serve as biomarkers of resolution status in inflammatory conditions.
• CRISPR-based editing of lipoxin pathway genes enables causal studies in disease models.
• Modulating lipoxin biosynthesis may enhance resolution in colon cancer and other inflammation-driven diseases.
• Understanding this pathway supports development of pro-resolving therapeutics.
What Happens During lipoxin biosynthetic process?
Release of arachidonic acid from membrane phospholipids
In simple terms: The process starts when arachidonic acid is freed from cell membranes.
Lipoxin biosynthesis begins with the liberation of arachidonic acid from membrane phospholipids, typically by cytosolic phospholipase A2 (PLA2G4A). Arachidonic acid is an omega-6 fatty acid that serves as the precursor for eicosanoids, including lipoxins. This release step is a prerequisite for subsequent enzymatic oxygenation.
Lipoxygenase-mediated oxygenation
In simple terms: Enzymes called lipoxygenases add oxygen to arachidonic acid to create intermediate molecules.
Arachidonic acid is oxygenated by lipoxygenases such as 5-lipoxygenase (ALOX5), 12-lipoxygenase (ALOX12), and 15-lipoxygenase (ALOX15). These enzymes insert molecular oxygen at specific positions to generate hydroperoxyeicosatetraenoic acids (HPETEs) and related intermediates. The specific lipoxygenase involved determines the stereochemistry and type of lipoxin produced.
Conversion to lipoxin A4 and isomers
In simple terms: The intermediates are converted into lipoxins, the final signaling molecules.
The lipoxygenase-derived intermediates undergo further enzymatic or non-enzymatic reactions to form lipoxin A4 (LXA4) and its isomers, such as lipoxin B4. These molecules contain four conjugated double bonds and are the bioactive products of the pathway. The biosynthetic routes can involve sequential actions of different lipoxygenases or transcellular metabolism.
Transcellular biosynthesis
In simple terms: Different cell types can cooperate to make lipoxins.
Lipoxin biosynthesis often occurs through transcellular routes, where one cell type produces an intermediate that is taken up and further metabolized by another cell type. For example, leukocyte 5-lipoxygenase and platelet 12-lipoxygenase can cooperate to generate lipoxins. This cooperation expands the cellular sources of lipoxins and integrates signals across cell populations.
Receptor interaction and signaling
In simple terms: Once made, lipoxins bind to receptors to send anti-inflammatory signals.
Lipoxins act through the ALX/FPR2 receptor to promote resolution of inflammation, including neutrophil apoptosis and macrophage efferocytosis. This signaling is a key functional outcome of the biosynthetic process and links lipoxin production to tissue homeostasis.
Key Genes Involved in GO:2001301 lipoxin biosynthetic process
The following genes encode enzymes and receptors that are directly involved in or regulate the lipoxin biosynthetic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALOX5 | 5-lipoxygenase; converts arachidonic acid to 5-HPETE and leukotriene A4, a precursor for lipoxins | Central enzyme in lipoxin and leukotriene biosynthesis; target for anti-inflammatory drugs |
| ALOX12 | 12-lipoxygenase; oxygenates arachidonic acid and participates in transcellular lipoxin synthesis | Contributes to lipoxin A4 formation in platelets and other cells |
| ALOX15 | 15-lipoxygenase; generates 15-HETE and related intermediates for lipoxin biosynthesis | Key enzyme in lipoxin and resolvin pathways; implicated in inflammation resolution |
| ALOX15B | 15-lipoxygenase-2; alternative lipoxygenase with roles in eicosanoid metabolism | May contribute to lipoxin production in specific tissues |
| LTA4H | Leukotriene A4 hydrolase; converts LTA4 to LTB4 and can influence lipoxin precursors | Modulates the balance between pro-inflammatory leukotrienes and pro-resolving lipoxins |
| FPR2 | ALX/FPR2 receptor for lipoxin A4; mediates anti-inflammatory signaling | Primary receptor for lipoxin action; target for pro-resolving therapeutics |
| PLA2G4A | Cytosolic phospholipase A2; releases arachidonic acid from membranes | Upstream regulator of all eicosanoid biosynthesis, including lipoxins |
| PTGS2 | Cyclooxygenase-2; can contribute to eicosanoid metabolism and influence lipoxin synthesis | Cross-talk between prostaglandin and lipoxin pathways |
| CYP1A1 | Cytochrome P450 enzyme; can metabolize arachidonic acid to epoxyeicosatrienoic acids | Potential alternative route affecting lipoxin precursor availability |
| CYP1B1 | Cytochrome P450 enzyme; participates in arachidonic acid metabolism | May influence eicosanoid balance and lipoxin biosynthesis |
| EPHX2 | Soluble epoxide hydrolase; metabolizes epoxyeicosatrienoic acids | Indirectly affects arachidonic acid metabolite pools |
| ALOX5AP | 5-lipoxygenase activating protein; required for ALOX5 activity | Essential for leukotriene and lipoxin biosynthesis; drug target |
| LTB4R | Leukotriene B4 receptor; mediates pro-inflammatory signaling | Contributes to the inflammatory milieu that lipoxins resolve |
| NFKB1 | Transcription factor regulating inflammatory gene expression | Controls expression of lipoxygenases and inflammatory mediators |
| PPARG | Peroxisome proliferator-activated receptor gamma; anti-inflammatory nuclear receptor | Modulates lipoxin biosynthesis and resolution pathways |
| IL10 | Anti-inflammatory cytokine; promotes resolution | Regulates lipoxin production and anti-inflammatory signaling |
| TNF | Pro-inflammatory cytokine; can alter lipoxin biosynthesis | Influences the balance between inflammation and resolution |
| STAT3 | Transcription factor involved in inflammation and cancer | May regulate lipoxin pathway genes in cancer |
How Is lipoxin biosynthetic process Regulated?
Lipoxin biosynthesis is regulated at multiple levels, including substrate availability, enzyme expression, and transcellular cooperation. The release of arachidonic acid by PLA2G4A is a rate-limiting step influenced by inflammatory stimuli. Expression of lipoxygenases such as ALOX5, ALOX12, and ALOX15 is controlled by transcription factors including NFKB1 and PPARG, which respond to inflammatory signals. Anti-inflammatory cytokines like IL10 can promote lipoxin production, whereas pro-inflammatory cytokines such as TNF may shift eicosanoid balance toward leukotrienes. Additionally, the ALX/FPR2 receptor mediates feedback regulation of resolution programs. Post-translational modifications and cellular localization of lipoxygenases further modulate pathway activity.
lipoxin biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALOX5 | Inflammatory diseases, asthma, cancer | Knockout and point-mutation models to dissect enzyme activity |
| ALOX15 | Inflammation resolution, cancer | Overexpression and knockout models to assess lipoxin production |
| FPR2 | Chronic inflammation, impaired resolution | Knock-in reporter and knockout models for receptor signaling |
| PLA2G4A | Inflammatory diseases, eicosanoid imbalance | Conditional knockout to study substrate release |
| LTA4H | Leukotriene-lipoxin balance, inflammation | Point-mutation models to alter enzymatic activity |
Lipoxin biosynthesis in inflammation and resolution
Impaired lipoxin biosynthesis is associated with chronic inflammatory diseases, where insufficient pro-resolving mediators lead to persistent neutrophil infiltration and tissue damage. Lipoxins act through ALX/FPR2 to promote neutrophil exit and macrophage clearance, and defects in this pathway can perpetuate inflammation. Enhancing lipoxin production is therefore a therapeutic strategy for inflammatory conditions.
Lipoxin biosynthesis in cancer
Dysregulated eicosanoid metabolism, including altered lipoxin biosynthesis, has been observed in colon cancer and other malignancies. Integration of lipidomics with transcriptomics has defined an unresolved pro-inflammatory state in colon cancer, suggesting that lipoxin pathway components may influence tumor progression and resolution. Targeting lipoxin biosynthesis could modulate the tumor microenvironment.
Lipoxin biosynthesis in other diseases
Lipoxins and their biosynthetic enzymes have been implicated in a range of diseases, including asthma, cardiovascular disease, and neurodegeneration, where resolution failure contributes to pathology. The anti-inflammatory and pro-resolving actions of lipoxins make this pathway a broad therapeutic target. However, the specific contributions of individual biosynthetic enzymes require further study using genetic models.
From lipoxin biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ALOX5 loss alter lipoxin biosynthesis? | ALOX5 knockout cell line or mouse model |
| Does a specific ALOX15 point mutation affect enzyme activity? | Point-mutation knock-in via CRISPR |
| Can tagged ALOX12 track transcellular lipoxin synthesis? | Tagged knock-in (e.g., GFP) in relevant cell types |
| Does FPR2 overexpression enhance resolution signaling? | Overexpression cell model |
| What is the role of PLA2G4A in arachidonic acid release? | Conditional knockout or knockdown |
| Can CRISPR library screening identify novel lipoxin regulators? | Genome-wide CRISPR knockout library in inflammatory cell models |
How to Study the lipoxin biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Targeted lipidomics (LC-MS/MS) | Quantification of lipoxins and eicosanoids | Measuring pathway output in cells and tissues |
| RNA-seq | Gene expression profiles | Identifying lipoxygenase expression changes |
| Single-cell RNA-seq | Cell-type-specific expression | Mapping cellular sources of lipoxin enzymes |
| Spatial transcriptomics | Spatial localization of gene expression | Tissue-level analysis of lipoxin pathway in cancer |
| CRISPR knockout screening | Gene function at scale | Discovering novel regulators of lipoxin biosynthesis |
| Flow cytometry | Neutrophil apoptosis and macrophage efferocytosis | Functional resolution assays |
| Western blot | Protein expression and modification | Validating enzyme levels in CRISPR models |
| Immunofluorescence | Protein localization | Tracking lipoxygenases in transcellular biosynthesis |
Lipidomics and mass spectrometry
Lipidomics coupled with mass spectrometry is the gold-standard method to quantify lipoxins and their precursors. Targeted lipidomics can measure LXA4 and related species in biological samples, and integration with transcriptomics provides a systems view of the biosynthetic pathway. This approach is essential for validating CRISPR models of lipoxin pathway genes.
Transcriptomics and single-cell analysis
RNA-seq and single-cell transcriptomics reveal expression patterns of lipoxygenases and associated genes across cell types. Spatial transcriptomics can localize lipoxin biosynthetic enzymes within tissues, as demonstrated in colon cancer studies. These methods help identify which cells contribute to lipoxin production.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes that regulate lipoxin biosynthesis or resolution signaling. Such screens are powerful for discovering novel pathway components and validating candidate genes in inflammatory and cancer models. Bioinformatics analysis of screening data prioritizes hits for follow-up.
Imaging and flow cytometry
Imaging techniques, including fluorescence microscopy and flow cytometry, can track neutrophil clearance and macrophage efferocytosis in response to lipoxins. These functional assays complement biochemical measurements and provide insight into resolution mechanisms.
How CRISPR Can Be Used to Study GO:2001301 lipoxin biosynthetic process
Knockout
CRISPR knockout of lipoxin pathway genes such as ALOX5, ALOX12, ALOX15, and FPR2 enables loss-of-function studies to determine their causal roles in lipoxin biosynthesis and resolution. Knockout cell lines and animal models can be used to measure changes in lipoxin production and inflammatory responses.
Point Mutation
Point mutations introduced by CRISPR base editing or homology-directed repair can model specific amino acid changes in lipoxygenases or the FPR2 receptor. Such models help dissect catalytic residues, substrate specificity, and receptor signaling without completely abolishing protein expression.
Knock-in
Knock-in of tags (e.g., GFP, HA) or reporter genes into endogenous loci allows tracking of lipoxin biosynthetic enzymes in real time. This approach is valuable for studying transcellular biosynthesis and subcellular localization of lipoxygenases.
Overexpression
CRISPR activation or lentiviral overexpression can increase expression of lipoxin biosynthetic genes to study gain-of-function effects. Overexpression models are useful for testing whether enhanced lipoxin production promotes resolution in disease models.
How EDITGENE Supports lipoxin biosynthetic process Research
Researchers studying lipoxin biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in lipoxin production, resolution signaling, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of lipoxin pathway components.
Contact EDITGENE today to design your custom CRISPR model for lipoxin biosynthetic process research.
Frequently Asked Questions About lipoxin biosynthetic process
What is GO:2001301 lipoxin biosynthetic process?
GO:2001301 is a Gene Ontology biological process term describing the chemical reactions and pathways that produce lipoxins, which are anti-inflammatory signaling molecules derived from arachidonic acid.
What genes are involved in lipoxin biosynthetic process?
Key genes include ALOX5, ALOX12, ALOX15, ALOX15B, LTA4H, PLA2G4A, and the receptor FPR2/ALX.
What are lipoxins and how are they made?
Lipoxins are non-classic eicosanoids with four conjugated double bonds, synthesized from arachidonic acid through lipoxygenase-mediated reactions.
Why is lipoxin biosynthesis important in inflammation?
Lipoxins promote resolution of inflammation by stimulating neutrophil clearance and macrophage efferocytosis, acting through ALX/FPR2.
How is lipoxin biosynthesis regulated?
It is regulated by substrate release via PLA2G4A, expression of lipoxygenases controlled by transcription factors like NFKB1 and PPARG, and cytokine signals such as IL10 and TNF.
What diseases are linked to lipoxin biosynthetic process?
Dysregulated lipoxin biosynthesis is associated with chronic inflammatory diseases, cancer, asthma, and cardiovascular disease.
How can CRISPR be used to study lipoxin biosynthesis?
CRISPR knockout, point mutation, knock-in, and overexpression models enable causal studies of lipoxin pathway genes in inflammation and cancer.
What methods measure lipoxin production?
Targeted lipidomics with mass spectrometry, RNA-seq, and functional assays such as flow cytometry are commonly used.
What is the role of ALOX5 in lipoxin biosynthesis?
ALOX5 (5-lipoxygenase) converts arachidonic acid to 5-HPETE and leukotriene A4, which are precursors for lipoxin synthesis.
What is the ALX/FPR2 receptor?
ALX/FPR2 is the receptor for lipoxin A4 that mediates anti-inflammatory and pro-resolving signaling.
Conclusion
The lipoxin biosynthetic process (GO:2001301) is a critical biological pathway that generates anti-inflammatory and pro-resolving mediators from arachidonic acid. Its dysregulation contributes to chronic inflammation and cancer, making it a compelling target for therapeutic intervention. Advances in CRISPR-based models and multi-omics methods now allow researchers to dissect the causal roles of lipoxin pathway genes with unprecedented precision. Continued investigation of this pathway promises to yield new strategies for resolving inflammation and improving disease outcomes.
References
- 1. Innes JK et al.. 2018. Omega-6 fatty acids and inflammation.. Prostaglandins Leukot Essent Fatty Acids 132:41-48 PMID: 29610056
- 2. Wang B et al.. 2021. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.. Signal Transduct Target Ther 6(1):94 PMID: 33637672
- 3. Soundararajan R et al.. 2025. Integration of lipidomics with targeted, single cell, and spatial transcriptomics defines an unresolved pro-inflammatory state in colon cancer.. Gut 74(4):586-602 PMID: 39658263
- 4. Peh HY et al.. 2024. 15-epi-lipoxin A(5) promotes neutrophil exit from exudates for clearance by splenic macrophages.. FASEB J 38(14):e23807 PMID: 38989570
- 5. Stenvik Haatveit Å et al.. 2023. The biosynthetic pathways of the protectins.. Prostaglandins Other Lipid Mediat 169:106787 PMID: 37806439
- 6. Saqib U et al.. 2025. Lipoxins as Modulators of Diseases.. Cells 14(16) PMID: 40862723
- 7. Sánchez-García S et al.. 2023. Lipoxin-mediated signaling: ALX/FPR2 interaction and beyond.. Pharmacol Res 197:106982 PMID: 37925045
- 8. Rokach J et al.. 1988. The lipoxins.. Int J Biochem 20(8):753-8 PMID: 3139479
